

Amendments to the claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original): A method of treatment of psoriasis which comprises administering to a patient in need thereof by the oral route a pharmaceutical composition comprising rosiglitazone, or a pharmaceutically acceptable salt or solvate thereof, together with a pharmaceutically acceptable carrier, wherein the method comprises administering 2 to 8 mg rosiglitazone per day.
2. (Original): A method according to claim 1 wherein the method comprises administering 2mg rosiglitazone per day.
3. (Original): A method according to claim 1 wherein the method comprises administering 4mg rosiglitazone per day.
4. (Original): A method according to claim 1 wherein the method comprises administering 8mg rosiglitazone per day.
5. (Currently amended): A method according to claim 1 any one of claims 1 to 3 wherein the method comprises administering the rosiglitazone once per day in a single dose or sequentially in two or more divided doses.
6. (Currently amended): A method according to claim 1 any one of claims 1 to 5 wherein the patient is suffering from moderate to very severe psoriasis.
7. (Currently amended): A method according to claim 1 any one of claims 1 to 6 wherein the treatment is continued for 12 weeks or more.
8. (Currently amended): A method according to claim 7 wherein the treatment is continued for 18 weeks or more.
9. (Currently amended): A method according to claim 1 any one of claims 1 to 8 wherein the rosiglitazone is employed as its maleate salt.
10. (Original): A method of treatment of psoriasis in a patient which comprises
 - (a) diagnosing psoriasis in a patient

(b) administering to said patient by the oral route a pharmaceutical composition comprising rosiglitazone, or a pharmaceutically acceptable salt or solvate thereof, together with a pharmaceutically acceptable carrier, in an amount of 2 to 8 mg rosiglitazone per day.

11. (Original): A method according to claim 10 which is a method of treatment of moderate to very severe psoriasis and step (a) comprises diagnosing moderate to very severe psoriasis in the patient.

12. (Currently amended): A method according to claim 10 ~~or claim 11~~ wherein in step (a) the patient is diagnosed with severe or very severe psoriasis.

13. (Currently amended): A method according to ~~claim 10 any one of claims 10 to 12~~ wherein in step (b) the rosiglitazone is administered once per day in a single dose or sequentially in two or more divided doses.

14. (Currently amended): A method according to ~~claim 10 any one of claims 10 to 13~~ wherein in step (b) rosiglitazone is administered to a patient for a continuous period of 12 weeks or more.

15. (Original): A method according to claim 14 wherein in step (b) rosiglitazone is administered to a patient for a continuous period of 18 weeks or more.

16. (Currently amended): A method according to ~~claim 1 any one of claims 1 to 15~~ which also comprises administering another medicament effective in the treatment of psoriasis with fast onset of activity.

17. (Original): A method according to claim 16 wherein the another medicament effective in the treatment of psoriasis with fast onset of activity is administered until the rosiglitazone becomes effective.

18. (Currently amended): A method according to claim 16 ~~or claim 17~~ wherein the another medicament is hydrocortisone.

19. (Currently amended): A method according to ~~claim 1 any one of claims 1 to 18~~ wherein the patient also suffers from NIDDM non-insulin dependent diabetes mellitus.

20. (Currently amended): A method according to ~~claim 1 any one of claims 1 to 18~~ wherein the patient does not also suffers from NIDDM non-insulin dependent diabetes mellitus.

21. (Original): A kit for the treatment of psoriasis comprising:

(a) A pharmaceutical composition comprising 2 to 8 mg rosiglitazone optionally in the form of a pharmaceutically acceptable salt or solvate thereof together with a pharmaceutically acceptable carrier in a single dose or in two or more divided doses per day of treatment; and

(b) instructions directing the oral administration by a patient suffering from psoriasis of 2 to 8 mg rosiglitazone optionally in the form of a pharmaceutically acceptable salt or solvate thereof together with a pharmaceutically acceptable carrier per day of treatment.

22. (Original): A kit according to claim 21 wherein the instructions direct the oral administration by a patient suffering from psoriasis of 2 to 8 mg rosiglitazone optionally in the form of a pharmaceutically acceptable salt or solvate thereof together with a pharmaceutically acceptable carrier once per day of treatment in a single dose or sequentially in two or more divided doses.

23. (Currently amended): A kit according to claim 21 ~~or claim 22~~ wherein the rosiglitazone is employed as its maleate salt.

24. (Currently amended): A kit according to ~~claim 21 any one of claims 21 to 23~~ which also contains another medicament effective in the treatment of psoriasis with fast onset of activity.

25. (Original): A kit according to claim 24 including instructions to the patient to administer the another medicament effective in the treatment of psoriasis with fast onset of activity is administered until the rosiglitazone becomes effective.

26. (Currently amended): A kit according to claims 24 ~~or claim 25~~ wherein the ~~another~~ medicament is hydrocortisone.

27. (Currently amended): A kit according to ~~claim 21 any one of claim 21 to 26~~ wherein the patient also suffers from NIDDM non-insulin dependent diabetes mellitus.

28. (Currently amended): A kit according to claim 21 ~~any one of claim 21 to 26~~ wherein the patient does not also suffer from ~~NIDDM~~ non-insulin dependent diabetes mellitus.

Claims 29-45 (Cancelled).